Article
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Dec 2013
Pilotto Sara, Bria Emilio, Peretti Umberto, Massari Francesco, Garassino Marina, Pelosi Giuseppe, Tortora Giampaolo
Abstract excerpt
No abstract is available from the source.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.